Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Moderate Buy consensus from 16 analysts (13 buys, 1 strong buy, 1 hold, 1 sell) with an average 12‑month target of $35.00.
• Shares opened at $18.60 and were trading down ~7.3%, giving a market cap of $2.95B and placing the stock well below analyst targets (one‑year range $12.58–$23.77).
• Denali is a clinical‑stage neurodegenerative biotech using a proprietary Blood–Brain Barrier Transport Vehicle platform, with lead programs including an oral LRRK2 inhibitor for Parkinson’s and an anti‑TREM2 antibody for Alzheimer’s; last quarter it reported EPS of ($0.73), narrowly beating estimates of ($0.75).

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have earned an average recommendation of "Moderate Buy" from the sixteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, thirteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $35.00.

A number of research analysts have recently commented on DNLI shares. UBS Group started coverage on Denali Therapeutics in a research note on Wednesday, January 7th. They set a "buy" rating on the stock. Wall Street Zen cut Denali Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, April 25th. Stifel Nicolaus boosted their price target on Denali Therapeutics from $34.00 to $41.00 and gave the company a "buy" rating in a report on Thursday, March 26th. Leerink Partners lowered their price target on Denali Therapeutics from $40.00 to $35.00 and set an "outperform" rating for the company in a report on Wednesday, April 22nd. Finally, BTIG Research boosted their price target on Denali Therapeutics from $36.00 to $38.00 and gave the company a "buy" rating in a report on Wednesday, March 25th.

Denali Therapeutics Trading Down 7.3%

DNLI opened at $18.60 on Thursday. The stock has a market cap of $2.95 billion, a price-to-earnings ratio of -6.26 and a beta of 1.10. The stock's 50 day moving average price is $20.29 and its 200-day moving average price is $18.75. Denali Therapeutics has a one year low of $12.58 and a one year high of $23.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.16 and a current ratio of 9.16.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.02. During the same period in the prior year, the firm posted ($0.67) EPS. On average, equities analysts forecast that Denali Therapeutics will post -2.86 EPS for the current year.

Institutional Trading of Denali Therapeutics

Large investors have recently modified their holdings of the company. Foresite Capital Management VI LLC purchased a new stake in shares of Denali Therapeutics in the third quarter valued at approximately $14,520,000. AlphaQuest LLC boosted its holdings in shares of Denali Therapeutics by 224.1% in the third quarter. AlphaQuest LLC now owns 74,422 shares of the company's stock valued at $1,081,000 after purchasing an additional 51,458 shares during the period. Aberdeen Group plc boosted its holdings in shares of Denali Therapeutics by 23.4% in the third quarter. Aberdeen Group plc now owns 1,113,586 shares of the company's stock valued at $16,169,000 after purchasing an additional 210,835 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Denali Therapeutics by 18.5% in the third quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company's stock valued at $18,458,000 after purchasing an additional 198,207 shares during the period. Finally, Capricorn Fund Managers Ltd purchased a new stake in shares of Denali Therapeutics in the fourth quarter valued at approximately $1,027,000. Hedge funds and other institutional investors own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.